SCHEMBL17844444

SCHEMBL17844444

CC(OS(C)(=O)=O)(c1ccccc1)c1ccn[nH]1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
NR3C2 P08235 1/20 0.33
CYP19A1 P11511 1/20 0.33
KDM4E B2RXH2 1/20 0.32
SCN4A P35499 1/20 0.32
ESR2 Q92731 1/20 0.32
MAPK1 P28482 1/20 0.31
CHRM2 P08172 1/20 0.31
METAP2 P50579 1/20 0.30
CYP4F2 P78329 1/20 0.30
CYP4A11 Q02928 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8318529 0.79 NR3C2 (0.43) KMT2ANR3C2ESR2MAPK1
SCHEMBL17847831 0.69 CYP19A1 (0.46) MEN1POLBKMT2ACYP19A1KDM4E
SCHEMBL23355969 0.69 KMT2A (0.45) MEN1POLBKMT2ACYP19A1KDM4E
SCHEMBL30951901 0.63 CHRM2 (0.40) MEN1POLBKMT2ACYP19A1CHRM2
SCHEMBL10444252 0.63 KMT2A (0.38) POLBKMT2ANR3C2MAPK1
SCHEMBL24418034 0.62 HCAR2 (0.45) MEN1POLBKMT2ACYP19A1ESR2
SCHEMBL5873337 0.62 CES1 (0.39) KMT2ANR3C2MAPK1
SCHEMBL2106697 0.62 NR3C2 (0.38) KMT2ANR3C2MAPK1
SCHEMBL8318293 0.60 NR3C2 (0.38) NR3C2MAPK1CHRM2
SCHEMBL27684711 0.60 NR3C2 (0.40) NR3C2ESR2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233830-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN Laboratorios Del. Dr. Esteve, S.A. (ES) 2017-10-25 EP disclosed
WO-2016096126-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2016-06-23 WO disclosed